Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Clinical Trials Market Companies Parexel IQVIA Charles River Laboratory Omnicare Kendle Chiltern Pharmaceutical Product Development, LLC Major Market Segments Covered By Phase Phase 1 Phase 2 Phase 3 Phase 4 By Study Design Observational Study Interventional Study Expanded Access Study By Indication Autoimmune/Inflammation Rheumatoid arthritis Multiple Sclerosis Osteoarthritis Irritable Bowel Syndrome (IBS) Others Pain Management Chronic Pain Acute Pain Oncology Blood Cancer Solid Tumors Other CNS Condition Epilepsy Parkinson's Disease (PD) Huntington's Disease Stroke Traumatic Brain Injury (TBI) Amyotrophic Lateral Sclerosis (ALS) Muscle Regeneration Others Diabetes Obesity Cardiovascular Others By Geography North America U.S
Active metabolite characterisation whether smaller peptide fragments retain biological activity
This sequencing is preferred when the patient has no prior experience with either compound and the primary indication for BPC-157 isn't urgent GI protection
702 These results suggest that liproxstatin-1 improves recovery from SCI by inhibiting endothelial cell ferroptosis and maintaining the integrity of the blood-spinal barrier
Reduction of anion reversal potential subverts the inhibitory control of firing rate in spinal lamina I neurons: towards a biophysical basis for neuropathic pain
US$ 25.19
US$ 28.09
US$ 23.57
US$ 26.48
US$ 25.72
US$ 21.73
US$ 21.29
US$ 25.46
US$ 27.82
US$ 29.18
US$ 27.11